SVP, CHIEF HR OFFICER Davis Krista sold $60,000 worth of shares (1,000 units at $60.00), decreasing direct ownership by 2% to 49,059 units (SEC Form 4)

$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ANIP alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Davis Krista

(Last) (First) (Middle)
C/O ANI PHARMACEUTICALS, INC.
210 MAIN STREET WEST

(Street)
BAUDETTE MN 56623

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, CHIEF HR OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
12/11/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/11/2024 S(1) 1,000 D $60 49,059 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2024.
Remarks:
/s/ Krista Davis, by attorney-in-fact Meredith W. Cook 12/12/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ANIP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ANIP

DatePrice TargetRatingAnalyst
12/11/2024$80.00Outperform
Leerink Partners
10/11/2024$68.00Overweight
Piper Sandler
3/15/2024$80.00Overweight
CapitalOne
8/22/2023$60.00 → $73.00Buy
H.C. Wainwright
3/1/2023$55.00Buy
Guggenheim
9/7/2022$50.00Buy
H.C. Wainwright
11/2/2021$60.00 → $65.00Outperform
Raymond James
11/2/2021$70.00Buy
Truist
More analyst ratings

$ANIP
Press Releases

Fastest customizable press release news feed in the world

See more
  • ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March

    PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of senior management, will present at two upcoming investor conferences as follows: Raymond James & Associates' 46th Annual Institutional Investors ConferenceTuesday, March 4, 2025, at 1:40pm ET Leerink Partners Global Healthcare ConferenceTuesday, March 11, 2025, at 3:40pm ET The live and archived webcasts will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be acce

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

    PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, February 28, 2025  Time8:00 a.m. ET  Toll free (U.S.) 800-579-2543  Conference ID4860276  Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section  

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

    PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the Guggenheim Biotech Conference in New York City as follows:   Date:Wednesday, February 5, 2025Time:2:00pm ESTWebcast:Click here   The live and archived webcast will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 60 days. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) i

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANIP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ANIP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANIP
SEC Filings

See more

$ANIP
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for HYDROCODONE BITARTRATE AND IBUPROFEN

    Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for OXYCODONE AND ASPIRIN

    Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FDA Approval for EZETIMIBE AND SIMVASTATIN

    Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANIP
Leadership Updates

Live Leadership Updates

See more
  • Alcami Announces CEO Transition

    Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries  DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran. "On behalf of the Board, I'd like to express gratitude to Bill for his leadership

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals Appoints Healthcare Executive Matthew J. Leonard to its Board of Directors

    -- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer

    ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANIP
Financials

Live finance-specific insights

See more
  • ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

    PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, February 28, 2025  Time8:00 a.m. ET  Toll free (U.S.) 800-579-2543  Conference ID4860276  Webcast (live and replay) www.anipharmaceuticals.com, under the "Investors" section  

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

    For full year 2024, the Company expects total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be at or above the guidance ranges provided on November 8, 2024Rare Disease Segment performed in line with expectations, with Purified Cortrophin Gel net revenues of $197.8 million to $198.4 million for the full year 2024 and ILUVIEN and YUTIQ net revenues of $30.4 million to $31.0 million for the post-acquisition period from September 16, 2024 to December 31, 2024, based on preliminary, unaudited resultsEstablished preliminary financial outlook for 2025, including total net revenues of $739 million to $759 million and adjusted non-GAAP EBITDA of $182 million to $192 mil

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance

    Generated record quarterly net revenues of $148.3 million, representing year-over-year growth of 12.5%, and record Purified Cortrophin® Gel net revenues of $52.6 million, an increase of 76.8% year-over-yearNet loss of $(24.2) million and adjusted non-GAAP EBITDA of $35.1 millionDiluted GAAP loss per share of $(1.27) and adjusted non-GAAP diluted earnings per share of $1.34Completed the acquisition of Alimera Sciences, Inc. on September 16, 2024, adding two commercial assets ILUVIEN® and YUTIQ® with significant growth potential to its Rare Disease portfolioImplemented new capital structure that is expected to reduce interest expense by approximately $39.0 million on an annualized basis (1)Inc

    $ANIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANIP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more